EMOLLIENTS IN ATOPIC DERMATITIS TREATMENT IN CHILDREN: CLINICAL AND PHARMACO-ECONOMICAL EFFICACY ANALYSIS

  • Authors: Kamaev AV1, Trusova OV2, Lyashenko NL1, Makarova IV2,3
  • Affiliations:
    1. Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St.-Petersburg State Medical University of the Ministry of Healthcare of Russian Federation
    2. St.-Petersburg State Pediatric Medical University
    3. The Health Committee of St.-Petersburg
  • Issue: Vol 14, No 4-5 (2017)
  • Pages: 98-107
  • Section: Articles
  • URL: http://rusalljournal.ru/raj/article/view/301
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Background. Even the mild course of atopic dermatitis (AD) requires the complex approach to the exacerbation therapy and prevention. Systematic skin care is the cornerstone of AD antirelapse therapy, but the emollients price might interfere the compliance. The study aim was to evaluate clinical effectiveness and pharmacoeconomics of therapeutic skin care complex Atopic (daily cream, reliver cream and shower gel) in children with AtD. Materials and methods. Open prospective evaluation of 1-month long. There were 50 children (6 month to 18 years old) with AtD included in 2 groups (exacerbation and remission, 25 children each). We have evaluated mean values of SCORAD index, skin itching and dryness (visual analog scales), pharmacotherapy requests and number of AtD exacerbations. Emollients’ consumption was determined by used packs’ weighting. Month total emollients’ outlay and 1 remission day cost with the Atopic therapeutic skin care complex application were calculated. Results. 47 patients (94%) had completed the protocol; 3 children had stopped Atopic applications due to individual intolerance. After 1 month in AtD exacerbation group mean SCORAD-index score had decreased from 41,8±4,6 to 13,4±2,7 (р=0,0001); in remission group initially low SCORAD results (7,2±0,9) hadn’t changed (6,3±1,8). Among outlay subgroups the daily cream cost was predominant. Mean 1 remission day cost was 72.9 and 52.4 rubles/day for groups 1 and 2, respectively. Conclusions. Gathered data allow to characterize Atopic complex as attractive quality/price ratio cosmetics and to recommend their wide usage in long-term anti-relapse AtD therapy in children.

Restricted Access

A V Kamaev

Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St.-Petersburg State Medical University of the Ministry of Healthcare of Russian Federation

Email: andykkam@mail.ru
6/8, L. Tolstoy, str., St.-Petersburg, 197089, Russia

O V Trusova

St.-Petersburg State Pediatric Medical University

2, Litovskaya str., St.-Petersburg, 194100, Russia

N L Lyashenko

Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St.-Petersburg State Medical University of the Ministry of Healthcare of Russian Federation

6/8, L. Tolstoy, str., St.-Petersburg, 197089, Russia

I V Makarova

St.-Petersburg State Pediatric Medical University; The Health Committee of St.-Petersburg

2, Litovskaya str., St.-Petersburg, 194100, Russia; 1, Malaya Sadovaya str., St.-Petersburg, 191023, Russia

  1. Федеральные клинические рекомендации по диагностике и лечению атопического дерматита. РААКИ. М., 2013, 27 с. Доступно по: http://www.nrcii.ru/docs/4.atopic_dermatitis.pdf
  2. Deckers I, McLean S, Linssen S, Mommers M, van Schayck C, Sheikh A. Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990-2010: A Systematic Review of Epidemiological Studies. PLoS ONE. 2012;7:e39803. doi: 10.1371/journal.pone.0039803.
  3. Flohr C, Mann J. New approaches to the prevention of childhood atopic dermatitis. Allergy. 2013;69:56-61. DOI: 10.1111/ all.12343.
  4. Campbell D. Role of food allergy in childhood atopic dermatitis. Journal of Paediatrics and Child Health. 2011;48:1058-1064. doi: 10.1111/j.1440-1754.2011.02125.x.
  5. Werfel T, Ballmer-Weber B, Eigenmann P, Niggemann B, Rancé F, Turjanmaa K et al. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. Allergy. 2007;62:723-728. doi: 10.1111/j.1398-9995.2007.01429.x.
  6. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch. Dermatol. 2001;137:1079-1081.
  7. Simpson E, Chalmers J, Hanifin J, Thomas KS, Cork MJ, McLean WI et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology. 2014;134:818-823. doi: 10.1016/j.jaci.2014.08.005.
  8. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. Journal of the European Academy of Dermatology and Venereology. 2012;26:1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x.
  9. Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T et al. S2k guideline on diagnosis and treatment of atopic dermatitis - short version. Allergo Journal International. 2016;25:82-95. doi: 10.1007/s40629-016-0110-8.
  10. Атопический дерматит у детей. Клинические рекомендации. Союз педиатров России, Российская Ассоциация Аллергологов и Клинических Иммунологов, Российское общество дерматовенерологов и косметологов. 2016, 60 с. Доступно по: http://www.pediatr-russia.ru/sites/default/ files/file/kr_ad.pdf
  11. National Institute for Health and Clinical Excellence. Management of atopic eczema in children from birth up to the age of 12 years. December 2007. Available from: http://guidance. nice.org.uk/CG57/Guidance/pdf/English.
  12. Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases. Advances in Therapy. 2017;34:1989-2006. doi: 10.1007/s12325-017-0582-z.
  13. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23-31.
  14. Воробьев ПА. Клинико-экономический анализ. - М.: Ньюдиамед; 2008.
  15. ОСТ «Клинико-экономические исследования. Общие положения». 91500.14.0001-2002. Доступно по: http:// docs.cntd.ru/document/1200123394
  16. Van Zuuren E, Fedorowicz Z, Arents B. Performance and Tolerability of the Moisturizers Cetaphil® and Excipial® in Atopic Dermatitis: What is the Evidence Based on Randomized Trials? Dermatology and Therapy. 2017;7:331-347. doi: 10.1007/s13555-017-0184-3.
  17. Nolan K, Marmur E. Moisturizers: Reality and the skin benefits. Dermatologic Therapy. 2012;25:229-233. DOI: 10.1111/j. 1529-8019.2012.01504.x.
  18. Камаев АВ, Трусова ОВ, Камаева ИА. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля. РМЖ. 2015;(3):142-146
  19. Mason J, Carr J, Buckley C, Hewitt S, Berry P, Taylor J, Cork MJ. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatology. 2013;13. doi: 10.1186/1471-5945-13-7.
  20. Деркач ВВ, Просекова ЕВ, Виноходова ГВ, Сергиенко ИС. Фармакоэкономические аспекты терапии атопического дерматита у детей. Тихоокеанский медицинский журнал. 2004;(3):73-76

Views

Abstract - 5

PDF (Russian) - 0

Refbacks

  • There are currently no refbacks.

Copyright (c) 2017 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies